NDC 66658-230 – Synagis

Palivizumab 50 mg/.5mL · Injection, Solution · Intramuscular

Human Prescription Drug

Product NDC66658-230

Product details

Brand name
Synagis
Generic name
Palivizumab
Labeler
Swedish Orphan Biovitrum AB (publ)
Dosage form
Injection, Solution
Route
Intramuscular
Marketing category
BLA · BLA103770
Marketed since
December 9, 1999
Marketing end
September 30, 2026
Pharmacologic class
Respiratory Syncytial Virus Anti-F Protein Monoclonal Antibody

Active ingredients

Uses, dosage, side effects and warnings for Synagis →

Package NDC codes (1)

Package NDCDescriptionSince
66658-230-01.5 mL in 1 VIAL, SINGLE-DOSE (66658-230-01)Sep 28, 2005